重组人红细胞生成素治疗晚期非小细胞肺癌化疗相关贫血疗效的观察

Recombinant Human Erythropoietin Therapy for Chemotherapy-induced Anemia in Patients with Non-small Cell Lung Cancer

目的 观察重组人红细胞生成素 (rhEPO)对晚期非小细胞肺癌 (NSCLC)化疗所致贫血的疗效。方法 选择 5 8例晚期NSCLC采用以铂剂为主联合化疗方案所致贫血患者 ,分为两组 ,EPO治疗组 2 8例给予皮下注射rhE PO ,剂量为 15 0 μg/kg ,3次 /周。对照组 30例不给予EPO治疗 ,仅给予五参芪口服液 ,10ml,3次 /日。 结果 治疗后 4周起EPO治疗组患者血红蛋白 (Hb)、红细胞压积 (HCT)、红细胞总数 (RBC)均明显上升 ,与治疗前相比差异有显著性 (P值 <0 0 1) ,与对照组相比差异有显著性 (P <0 0 5 )。EPO治疗组总有效率为 89 3% ,对照组为37 1% ,差异有显著性 (P值 <0 0 1)。结论 EPO对晚期NSCLC采用以铂剂为主联合化疗方案所致贫血有肯定的疗效。

Objective To investigate the effect of recombinant human erythropoietin (rhEPO) therapy for chemotherapy induced anemia in patients with non small cell lung cancer (NSCLC). Methods Forty eight chemotherapy induced anemic patients with NSCLC were divided into 2 groups: rhEPO treatment group ( n =28) subject to subcutaneous injection of rhEPO (150 μg/kg), 3 times every week; control group not subject to rhEPO. Results From the 4th week after therapy, the Hb, HCT, RBC in the rhEPO treatment group was significantly increased as compared with those before treatment ( P <0 01) and control group ( P <0 05). The overall response rate of the rhEPO treatment group was 89 3 %, significantly higher than that of the control (37 1 %). Conclusion The curative effect of rhEPO on the chemotherapy induced anemia in patients with NSCLC was definitely positive.